🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
1.360
0.00 (0.00%)
Nov 19, 2026, 4:00 PM EST - Market closed
← View all transcripts

3rd Annual Guggenheim Healthcare Innovation Conference

Nov 10, 2026

Summary

DENALI reported 37% ORR and 5.5-month response duration, with encouraging OS in Cyclin E1-high patients; enrollment is expected to conclude by end-Nov 2026, with data guided for H1 2027. Development also targets earlier ovarian disease and triple-negative breast cancer.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

To this next fireside chat with Zentalis. My name is Michael Schmidt, and I am pleased to welcome Julie Eastland, CEO of Zentalis. Julie, welcome. Thanks for joining us.

Julie Eastland
CEO, Zentalis

Thank you, as always. Appreciate the invite to the conference.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

Maybe for those who are just getting to know Zentalis, Julie, what is the core idea behind the company, azenosertib, and why is Cyclin E1-positive ovarian cancer the right place to start with this asset?

Julie Eastland
CEO, Zentalis

Those are excellent questions. I first, before I begin, just want to make note that there is likely going to be questions that will require some forward-looking statements, including some estimates and projections, and we advise folks to review our filings with the SEC for risk factors associated with those. We did just report earnings and a corporate update today, so we can certainly talk about some of those things as a backdrop, of course. Zentalis is focused on developing meaningful new therapies for oncology indications, and our lead program, and our main program is azenosertib. azenosertib is a small molecule WEE1 inhibitor. Its focus in Cyclin E1 ovarian cancer has really been derived from a vast body of data of studying azenosertib in the clinical setting across different studies in the ovarian cancer setting.

That is, as a dose escalation study that was first designed to understand dose and schedule, and then in addition to that, combination trials and single-agent trials in ovarian. What we've found as we've looked back to understand patient populations that we believe would benefit most in ovarian cancer, we have identified a group of patients that are defined as Cyclin E1-positive patients. That definition is patients who have Cyclin E1 protein expressions at levels that meet a bar where we see a high correlation of response to that protein expression. Importantly, I think we are working to help folks understand that protein expression differs from gene amplification, and that is that protein expression is both the result of gene amplification and other factors, and is broader than whether or not your gene is amplified for CCNE1.

Importantly, we believe all patients should be screened, because even those patients without amplification can have high Cyclin E1 protein expression and could potentially benefit from azenosertib.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

I think the percentage is 50% of patients in ovarian cancer. Is that correct?

Julie Eastland
CEO, Zentalis

Yeah. In our historical studies, as well as looking back at real-world data, we estimate that approximately 50% of the PROC patients express Cyclin E1 levels that would meet our cutoff based on our IHC assay.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

Okay. And so we've seen the phase I-B, I guess, or phase II data a few times now in recent history, but the most recent update was really at ESMO here just a couple weeks ago. And so just remind us what the data showed and what it means for the program.

Julie Eastland
CEO, Zentalis

Yeah. It's exciting data. So DENALI is a phase II study. It had multiple parts. Part I-B read out initially in 2025, and the data at ESMO updated that and included new data around the overall survival of those patients. Importantly, this overall survival data of Cyclin E1 high expressors was in the range of almost 16 months of additional overall survival for that population, as compared to Cyclin E1 negative patients, which had about 7.5 months of OS. This really not only strengthens the overall profile of the agent, but also helps to really, again, define and complement the selection of Cyclin E1 high positive patients in this population as a group of patients that could benefit from azenosertib. We did update the ORR slightly.

There was one additional patient that had a response post the previous cutoff, so that response rate of response of valuable patients went up to 37%. And then we updated the duration of response as it matured. That is at 5.5 months, and certainly within the range and the bar in which we think is meaningful for these patients that have a tendency to do worse and progress more quickly.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

Right. And remind us, that's at the recommended phase II or phase III dose, I guess, correct?

Julie Eastland
CEO, Zentalis

Yeah, that's a really good point. In DENALI part I-B, all patients were dosed at 400 mg. That's on a schedule of five days on and two days off. That is the dose that was also selected in part two of this trial that looked at a dose comparison of 300 and 400.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

Okay.

Julie Eastland
CEO, Zentalis

Yes.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

How did tolerability look? I know it was a topic of discussion in the past.

Julie Eastland
CEO, Zentalis

Yeah, tolerability, we didn't update tolerability because there were no significant changes there in the DENALI I-B dataset from the prior presentation at SGO in 2025. But that tolerability overall is quite manageable. At 400 mg, we see three areas of interest. We look at GI tolerability, we look at fatigue, and we look at hematological. I think in particular, most of the grades here are low grade 1 and 2. And of areas of note, neutropenia has a low double-digit grade 3 incident rate in the DENALI I-B dataset. And of course, I think you're referring to, in that dataset, we did have two patients who had grade 5 related events. And we did announce in part two, in the first part of that dose comparison, we have had no grade 5 related events.

Part of that is just management and obviously how physicians are learning to use the agent and how we are learning to help patients and physicians utilize the agent.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

Okay, great. Just to put this in context, and maybe into your- As it pertains to Part 2C, which is your registration study, how do these data compare to expected performance of standard of care?

Julie Eastland
CEO, Zentalis

Sure. In DENALI Part 2, there is three components. There was first the dose comparison. I know it is confusing. Phase II study, multi-part. In Part 2, we had a dose bake-off. We call that 2A. There, we selected the 400 mg dose to be compliant not only with Project Optimus, but reconfirm the dose of interest from the earlier trials. In the second part, which we call 2B, that cohort of patients simply added additional patients at the 400 mg selected dose to come up to what we believe is a registration dataset in terms of population of patients. As we were enrolling this trial, two new agents were potentially coming to the market, and that included some taxane-based regimens. In order to enrich our dataset to include some of these agents and have experience in the population, we added a cohort called 2C.

We announced yesterday that that cohort is expected and is scheduled to be completed at the end of this month. Across our integrated database, those three parts I mentioned, A, B, and C, we expect to have up to about 30 patients in these sort of taxane-based regimens in the PROC setting. Importantly, most all patients see taxanes in first line, but some patients then also experience them again in PROC. To be clear, these are patients who have seen a taxane, either single agent or combination, in the PROC setting. We think we have enough patients to really understand the profile of that population and how azenosertib can treat patients post-taxane therapy. We are going to conclude enrollment on DENALI, and we look forward to data in the first half of next year, as we guided earlier.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

The data, this will be response rate and duration. Is that correct?

Julie Eastland
CEO, Zentalis

Correct.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

What is the expected standard of care doing in this context?

Julie Eastland
CEO, Zentalis

Oh yeah. Thank you for that. So, for us, we have been focused on, of course, what patients have available to them primarily, which is single-agent chemo. That is true on a global basis. That is still true today, where that is the most widely used agents. There are some new agents that have come to market, as we have mentioned, and those agents are likely being sold into and being adopted in the U.S. market, and I am sure will be as well outside the U.S. at some point. But at the end of the day, those patients will be part of our population. We will look to treat patients post these agents, especially in an accelerated approval path, where we have allowed one to four prior therapies for patients who have seen these taxane regimens.

Chemotherapy, and single-agent chemo in particular, is our bar, and that bar for overall response rate is very low in terms of what we have seen historically there. It is 11%-12% or so. If you were statistically to exclude that, you would probably need to see a response rate higher than 20%, low 20%. We think clinically meaningful response rates in this setting against single-agent chemo really are in the 30+ response rate. Certainly anywhere over five months in terms of duration would be meaningful compared to what we see historically in single-agent chemo.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

Yeah. One thing we hear a lot is there are a lot of ADC product candidates being evaluated in platinum-resistant ovarian cancer. Rina-S just had positive topline results reported. How do you think this product candidate fits into this emerging landscape where a lot more ADCs could potentially eventually reach the space?

Julie Eastland
CEO, Zentalis

Yeah. Yeah, it's great. I mean, let's look historically at ovarian cancer, where very little progress has been made. This is a win for patients. Couple things. ADCs, of course, effectively are, I'll describe them as new chemo. They're obviously a targeted way to deliver chemo. I think that's going to be an important agent, of course, in PROC, but also in earlier lines where many studies are being run with these ADCs. While ADCs, there are a number targeting folate receptor alpha and other targeted expression levels of different proteins, at the end of the day, their payload is Topo 1. We think of these as a class of agents. We do know, as we look at breast cancer, where treating patients with multiple Topo 1s doesn't usually provide any benefit.

In fact, I think in breast cancer, a Topo 1 agent post an initial had zero responses. As we talk to investigators and physicians, they feel that there will be a winner, or one or two of these that have a profile that will come to market and be used, and that most of those will move up into the earlier line, leaving, again, an absence of therapies in PROC. For us, ADCs are, we don't see those as competitive. We're talking about our agent, which is, of course, an oral agent, and ADCs are infused. Our agent is a non-chemo or non-ADC agent, and it's for Cyclin E1 patients. So, we have a differentiated profile that we think is complementary in the setting. At some point one day, we'd like to see ourselves before, after, or with, in combination with ADCs.

We're excited about what's coming for patients, but we see our market position and differentiation the same.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

Right. You obviously are also enrolling the ASPENOVA study. Remind us of what patients are enrolling in ASPENOVA relative to DENALI, and what we should think about the timing of that study.

Julie Eastland
CEO, Zentalis

Yeah. Thanks. ASPENOVA is the phase III randomized trial. It is also in Cyclin E1 high expressors. Again, these are patients that are prospectively screened for their status and then enrolled in the trial. That is the same in DENALI as it is in ASPENOVA. Also in ASPENOVA, the population is similar in terms of patients who have had one to three prior lines of therapy are eligible to enroll. If patients have an indication and are able to see mirvetuximab, then of course they can have that as well, and that would be one to four prior lines. It is a controlled trial, and the investigator's choice in terms of the control arm is single-agent chemo.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

Okay. Any plans of advancing earlier down the road? There is obviously more opportunity in ovarian cancer, be it in earlier lines or in combination, and maybe in other cancer types. Do you have any plans along those lines?

Julie Eastland
CEO, Zentalis

Yeah, we not only have plans, but we actually have a trial enrolling patients in the second-line maintenance setting in ovarian cancer. That is azenosertib plus bevacizumab. That is looking at patients who have progressed while on a PARP inhibitor in the first-line setting, and they come into the second-line maintenance setting, and we kind of understand what their PFS prognosis will be. We have a combination there where we expect to enroll, and we have already selected the combination dose. We are right now in sort of the expansion enrollment in that trial, and we hope to have data for that at some point in 2027. We will be able to provide more guidance as the enrollment nears completion there. But we also have interest because azenosertib can make for a great partner with cytotoxic agents.

We are planning a combination trial in triple-negative as well, and we do expect that to start at some point in 2027. We will be able to provide some more color and guidance on that as we complete our planning around that. We think this was a real This has always been our strategy.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

Yeah.

Julie Eastland
CEO, Zentalis

You know, PROC and monotherapy, because we had the most data, get there first. Certainly expand into ovarian earlier lines. That is the MUIR trial. Then really bring the full value of azenosertib as a potential combination partner across other tumor types, and that is the triple-negative strategy. This was outlined in 2025, and we have the ability to continue to execute on that strategy here in 2026.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

Great. Then just to close, the size of the opportunity in PROC, how would you characterize that for azenosertib?

Julie Eastland
CEO, Zentalis

Sure. I mean, it is interesting. We have seen references to that by others, and we think that those estimates make sense. This is a patient population worldwide that azenosertib can reference of about 20,000 patients a year across major geographies, and we think that translates to a pretty significant size. I mean, if you want to look at an actual correlate, you could take a look, of course, at ELAHERE here and how its launch has been actually quite well, quite large in the U.S. and now in Europe. We see there in just the first couple years of launch that they are well over $600 million in sales. That is an opportunity that is about 35% of the PROC market, whereas we have about a 50% opportunity. By the way, the 20,000 patient represents the azenosertib potential PROC opportunity.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

Got you. Okay, cool. Thanks. What is your guidance in terms of the cash runway and some of the milestones over the next 12 to 18 months?

Julie Eastland
CEO, Zentalis

Yeah. Happy to talk about that. We certainly appreciate the support from the capital markets. That financing obviously not only allows us to complete the DENALI trial, it also allows us to enroll the ASPENOVA study. In addition, it allows us to think about talking to the regulators and move forward to a registration pathway, whether that's in DENALI or through ASPENOVA. It funds these additional combination trials that we talked about before. Clearly, should we have the opportunity to launch in the U.S. market through accelerated approval, we'll need to add capital associated with that for a market launch. That would be a good problem to have.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

Okay. What about ex-U.S.? Are you considering partnering this at some point in the future?

Julie Eastland
CEO, Zentalis

Yeah, I mean, obviously this is an agent that could have quite a lot of application. It's going to need deep pockets, and we welcome the opportunity to think about how do we move this drug to patients faster and broader. That may mean looking at partners. Certainly for the PROC setting, the U.S. market is something we think we can launch in, but ex-U.S., we would be looking for a partner to expand in a full approval setting once ASPENOVA reads out. So yes, we do think a partner would make a lot of sense.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

Okay, great. Well, thank you, Julie. That is all I had.

Julie Eastland
CEO, Zentalis

That is it.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

Appreciate the time.

Julie Eastland
CEO, Zentalis

Thank you. Good to see you.

Michael Schmidt
Senior Biotech Analyst, Guggenheim

Good to see you.